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Abstract
Background: Fibrolamellar Carcinoma (FLC), a subtype of hepatocellular carcinoma (HCC), is a
rare primary hepatic malignancy. Several aspects of the clinic features and epidemiology of FLC
remain unclear because most of the literature on FLC consists of case reports and small cases
series with limited information on factors that affect survival.
Methods: We did a retrospective analysis of the clinical and histological characteristics of FLC.
We also determined the rate of cellular proliferation in biopsies of these tumors. We assessed
whether these variables were associated with survival.
Results: We found 15 patients with FLC out of 174 patients with HCC (8.6%). Between patients
with these neoplasms, we found statistically significant survival, age at onset, level of alpha
fetoprotein, and an earlier stage of the disease. The 1, 3 and 5 year survival in patients with FLC
was of 66, 40 and 26% respectively. The factors associated with a higher survival in patients with
FLC were age more than 23 years, feasibility of surgical resection, free surgical borders, absence of
thrombosis or invasion to hepatic vessels and the absence of alterations in liver enzymes. The size
of the tumor, gender, cellular proliferation and atypia did not affect the prognosis.
Conclusion: We concluded that FLC patients diagnosed before 23 years of age have worse
prognosis than those diagnosed after age 23. Other factors associated with worse prognosis in this
study are: lack of surgical treatment, presence of positive surgical margins, vascular invasion, and
altered hepatic enzymes.
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Background
Hepatocellular carcinoma (HCC) is the most frequent pri-
mary neoplasm of the liver. Its incidence is increasing in
western countries mainly due to the growing Hepatitis C
Virus epidemics. Though potentially curable with surgery,
very few patients are candidates for resection because of
tumor extension and poor liver function at diagnosis. The
prognosis is poor, with a 1-year survival rate of 22.6% [1].
Fibrolamellar carcinoma (FLC) was described initially in
1958 by Edmonson, as a subtype of HCC [2]. It is charac-
terized by eosinophilic polygonal cells and wide bands of
fibrotic tissue settled in parallel laminas surrounded by a
clustering of tumor cells [3-6]. It has not been linked with
hepatic viruses, alcohol, estrogen use, or other risk factors
traditionally associated with HCC. It occurs more fre-
quently in children and adults less than 35 years old. It
also exhibits a slower clinical course than the more com-
mon HCC. Controversy exists whether FLC has a better
prognosis than HCC. Small retrospective series have
shown a better survival after resection compared to HCC
[4,7-10]. Nevertheless, a recent study of 10 patients with
FLC did not report a difference in survival compared to 36
patients with classic HCC [11].
The differences in the prognosis of these patients are prob-
ably a consequence of a non cirrhotic liver and the
expanding nature tumor growth permits a high rate of sur-
gical resection. In contrast to classic HCC, which has well
defined prognostic factors such as Alfa fetoprotein levels,
performance status, liver function, and the severity of cir-
rhosis [12-14], no such predictive standards have been
elucidated for FLC. The aim of this study was to describe
the clinical, radiographic and histopathologic characteris-
tics of FLC and analyze the factors associated with sur-
vival.
Methods
Medical records of patients with the diagnosis of HCC
were reviewed in the Instituto Nacional de Ciencias Médi-
cas y Nutrición Salvador Zubirán from 1990 to 2003.
Patients with FLC were then identified from biopsy
results. Patients with incomplete medical records or lack-
ing biopsy results were excluded from the study.
Biopsies of patients with FLC were reviewed to confirm
the diagnosis; some samples where dyed again to deter-
mine histopathologic characteristics such as atypia and
mitosis index. Additional samples were analyzed by
immunohistochemistry with the avidin-biotin-peroxidase
complex and counterstained with hematoxylin; they were
incubated overnight at 4°C either with rabbit anti-human
proliferation cell nuclear antigen as a marker of cellular
synthesis phase. A pathologist of our institution, blinded
Fibrolamellar Hepatocarcinoma (400×), hematoxylin-eosin with big polygonal cells, and abundant eosinophil granular cytoplasm  (A) Figure 2
Fibrolamellar Hepatocarcinoma (400#215;), hematoxylin-eosin with big polygonal cells, and abundant eosinophil granular cyto-
plasm (A). Masson trichromic (100×) with cordons of hepatocytes separated with dense collagen septum (B). Immunohisto-
chemistry for PCNA that shows high index of cellular proliferation of the nucleus (C)
Survival analysis of patients with HCC (n = 159) compared  with FLC (n = 15) p = 0.007 Figure 1
Survival analysis of patients with HCC (n = 159) compared 
with FLC (n = 15) p = 0.007.
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to the results of survival, counted the number of cell
nuclei positive for nuclear antigen found per microscopy
field at × 40 magnification in 10 different fields [15].
The variables of survival, alpha fetoprotein, mitotic index
and cellular proliferation index were expressed as mean ±
standard error. The SPSS program version 10 was used for
the statistic analysis. Statistic significance was determined
as P < 0.05 with two-sided test. The Student's t test and the
chi square or Fisher's exact test was used to compare the
continuous variables with normal distribution and nomi-
nal variables of patients with classic HCC and FLC respec-
tively. Kaplan-Meier curves and log-rank was used for the
survival analysis. The multivariate analysis was done
using Cox regression modelling.
Results
We reviewed 174 medical records of patients with diagno-
sis of HCC and found 15 patients with FLC,(8.6%). Sev-
enty percent of the FLC patients were females compared to
37% of the classic HCC patients (p = 0.045). The average
age was lower in patients with FLC compared to patients
with HCC (23 ± 2.6 years with a range of 17–45 years vs
58 ± 1.5 years with a range of 22–87 years respectively p =
0.001). No patient with FLC had a previous history of
blood transfusions or a positive serology for hepatitis. In
contrast, 75% of patients with HCC had positive hepatitis
B and/or C virus serology (p = 0.0001). Thirty percent of
the patients with FLC reported use of oral contraceptives,
with a range of use of 6–60 months, versus 15% of the
patients with classic HCC (p = 0.1). Most common signs
and symptoms in patients with FLC were: right upper
quadrant pain 83%, hepatomegaly 75%, and weight loss
67%. In laboratory screening we found mean serum albu-
min of 3.05 ± 0.2 vs 2.9 ± 0.1 g/dL in patients with classic
HCC (p = 0.8). The alpha fetoprotein levels were signifi-
cantly lower in patients with FLC compared to patients
with classic HCC (81.5 ± vs 355.7 ± 65 ng/L, p = 0.003).
The patients with FLC and classic HCC presented stage I
27% vs 6% (p = 0.026), stage II 7% vs 16% (p = 0.46),
stage III 40 vs 67% (p = 0.042) and stage IV 27% vs 10%
(p = 0.1) respectively. The mean survival time of patients
with FLC was 30 ± 6.4 months vs 10.6 ± 3 of the classic
HCC (p = 0.007) (Figure 1).
In FLC, the most frequent radiographic studies done for
the diagnosis were CT scan in 92% of the patients, then
MRI in 67% and USG in 58%. The most frequent charac-
teristics found on CT scan were: solitary tumor (22% of
the patients), lymphadenopathy (14%), linear hypodense
images corresponding to central scar (13%), peripheral
reinforcement (12%). The MRI characteristics were central
scar (40%), defined contour (18%), more than one tumor
(12%), and multilobular contour (12%).
Histopathologic characteristics of FLC biopsies included
absence of cirrhosis, presence of fibrotic septum and gran-
ular cytoplasm. Furthermore, 92% of the patients demon-
strated polygonal cells. Also, 75% of the patients had mild
atypia with the remainder showing moderate atypia. In
addition, 42% of the biopsies demonstrated pseudoinclu-
sions; 42% had prominent nucleolus, while 33% showed
hepatic steatosis (Figures 2A and 2B). The mitotic index
average was 2± 1. In all tumors we found a high index of
cellular proliferation, mean of 90 ± 5. (Figure 2C).
Survival analysis of prognostic factors of patients with FLC Figure 4
Survival analysis of prognostic factors of patients with FLC. 
Age = 23 years (n = 7, median survival of 8 ± 2 months) com-
pared to age > 23 years (n = 8, median survival of 65 ± 19 
months), p = 0.0132.
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Global survival of patients with FLC at 6, 12, 24, 36 and 60  months was 66, 66, 53, 40 and 26% (median survival of 30 ± 6  months) Figure 3
Global survival of patients with FLC at 6, 12, 24, 36 and 60 
months was 66, 66, 53, 40 and 26% (median survival of 30 ± 6 
months).
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Surgical resection was performed in 80% of the FLC
patients. The most frequent procedures were exploratory
laparotomy with biopsy (40% of the patients), lobectomy
(20%) and segmentectomy (20%). 60% had free surgical
margins and 43% percent received chemotherapy. The
overall survival of patients with FLC at 6, 12, 24, 36 and
60 months was 66, 66, 53, 40 and 26% (Figure 3. The fac-
tors associated with a better survival were age 23 years or
more (median of the age) (8 ± 2 vs 65 ± 19 months; p =
0.0132) (Figure 4), resectability (absence of multiple
tumors in more than one lobe, absence of involvement of
a major branch of portal or hepatic veins and adequate
hepatic function) (60 ± 10 vs 5 ± 2 months; p = 0.001)
(Figure 5), negative surgical borders for tumor (65 ± 4 vs
20 ± 5 months; p = 0.06) (Figure 6), absence of thrombo-
sis or invasion to the hepatic vein (60 ± 10 vs 5 ± 2
months; p = 0.006) (Figure 7) and normal liver enzymes
(ALT and AST) (65 ± 21 vs 26 ± 11 months; p = 0.04) (Fig-
ure 8).
Factors unrelated to prognosis were gender (p = 0.646),
presence of palpable mass (p = 0.84), hepatomegaly (p =
0.68), weight loss (p = 0.64), ascites (p = 0.57), fever (p =
0.18), jaundice (p = 0.34), hemoglobin value (p = 0.52),
normal alkaline phosphatase (p = 0.68), hypoalbumine-
mia (0.9), increase in alpha fetoprotein (p = 0.67), level
of atypia (p = 0.31), mitotic index (p = 0.9), index of cel-
lular proliferation (p = 0.8) and TNM stage (p = 0.69).
Multivariate analysis showed only age greater than 23
years (p = 0.027) and absence of multiple tumors in more
than one lobe (p = 0.043) were associated with better sur-
vival.
Discussion
Fibrolamellar Hepatocarcinoma is a rare primary hepatic
malignancy constituting approximately 1% of all cases of
primary liver cancer. A recent retrospective study, the Sur-
veillance, Epidemiology and End Results (SEER) program
diagnosed only 68 cases of FLC out 7,896 cases of HCC
(0.86%); nevertheless, FLC made up 13.4% of all HCC
tumors in people below the age of 40 years [16]. In our
study, we found a much higher frequency of 8.6% (15 of
174 patients of all ages). Possibly the number of patients
with classic HCC was underestimated in our study as we
excluded all patients without biopsies. Almost all patients
lacking biopsy were those with advanced cirrhosis, a char-
acteristic of patients with classic HCC rather than FLC.
Our study showed a clear absence of association of FLC
with Hepatitis virus and the absence of elevation in alpha
fetoprotein compared to classic HCC [17].
Another interesting issue was the higher frequency of
female gender in the group of FLC compared to classic
HCC (60 vs 37%). This observation was also reported in
the SEER study where the authors found a higher propor-
tion of females (51.5 vs 26.3%) [16]. Some cases of FLC
have been reported during pregnancy [18-20]. In our
study, 56% of the female patients with FLC had oral con-
traceptive use. This was not significantly different from
classic HCC patients, but we cannot exclude a hormonal
influence in the physiopathology.
Survival analysis of prognostic factors of patients with FLC Figure 6
Survival analysis of prognostic factors of patients with FLC. 
Patients who underwent surgical treatment with positive (n = 
5, median survival of 20 ± 5 months) and negative (n = 5, 
median survival of 65 ± 4 months) surgical borders, p= 0.06.
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Survival analysis of prognostic factors of patients with FLC Figure 5
Survival analysis of prognostic factors of patients with FLC. 
Patients who underwent surgical treatment (n = 10, median 
survival of 60 ± 10 months) vs patients with medical treat-
ment only (n = 5, median survival of 5 ± 2 months), p = 
0.0011.
Months
70 60 50 40 30 20 10 0
S
u
r
v
i
v
a
l
%
100
80
60
40
20
Surgical resection
No Surgical resection
Log rank p=0.0011
5 ± 2 months
60 ± 10 monthsBMC Cancer 2005, 5:142 http://www.biomedcentral.com/1471-2407/5/142
Page 5 of 7
(page number not for citation purposes)
We found a significantly lower age at diagnosis in patients
with FLC, similar to results reported in the SEER study; the
age for FLC at diagnosis was 39 ± 20 vs 65 ± 13. A greater
proportion of patients with FLC were classified as having
localized disease (stage I) compared to patients with
HCC. Similar results were described by the SEER study,
where localized disease at diagnosis was seen in 41.2% of
FLC patients vs 30.9% of HCC patients. One of the main
radiological features found in our study was the presence
of central scar. A retrospective study analyzed different
radiological features in this kind of tumors and found cen-
tral scar 71% on CT scans and 82% on MRI in patients
with FLC [21].
A limitation of the SEER study was the absence of analysis
of factors that modified survival. We found important dif-
ferences in survival related to age; younger patients (less
than 23 years) had a worse prognosis than those who were
older. Another associated factor was the feasibility of sur-
gical resection (multiple tumors in more than one lobe)
and the presence of tumor in, and thrombosis of, liver ves-
sels independent of the tumor size. We found that histo-
logical characteristics such as atypia and cellular
proliferation index did not influence prognosis.
The marked differences in epidemiology and clinical
course indicate that FLC is distinct from HCC. We found
that patients with FLC had higher survival rates than
patients with HCC. These results are consistent with the
published literature. Some authors report a higher sur-
vival rate in patients with FLC after surgical resection,
compared to patients with HCC in absence of cirrhosis
[9]. In the SEER study they found that the 5 year survival
rate was 31.8% for FLC compared with 6.8% for HCC,
adjusting for differences in age, gender, race, stage of dis-
ease, receipt of resection or transplant, and time of diag-
nosis. FLC was independently associated with a 46%
reduction in risk of mortality [16]. Conversely, another
study found no difference in survival following surgical
resection between patients with FLC and those with HCC.
A multicenter trial of postresection chemotherapy (Pedi-
atric Oncology Study Group Study 8945/Children's Can-
cer Study Group 8881) compared the survival of 10
children with FLC and 36 with HCC, without finding dif-
ferences according to histology.
Conclusion
We concluded that FLC patients diagnosed before 23 years
of age have worse prognosis than those diagnosed after
age 23. Other factors associated with worse prognosis in
this study are: lack of surgical treatment, presence of pos-
itive surgical margins, vascular invasion, and altered
hepatic enzymes.
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Table 1: Association of global survival in patients with FLC to 
clinical and pathological characteristics.
Variable Survival (months) P (log rank)
Age
≤ 23 years 8 ± 2 0.013
> 23 years 65 ± 19
Gender
male 26 ± 6 0.646
female 42 ± 27
Surgical
resection 60 ± 10 0.011
No resection 5 ± 2
Surgical border
Positive 20 ± 5 0.06
Negative 65 ± 4
Fever
Present 67 ± 14 0.188
Absent 26 ± 7
Jaundice
Present 65 ± 19 0.345
Absent 26 ± 13
Palpable Mass
Present 42 ± 33
Absent 26 ± 14 0.84
Weight loss 
Present 26 ± 6 0.646
Absent 42 ± 27
Ascites 
Present 4 ± 32 0.578
Absent 42 ± 2
Hepatomegaly 
Present 42 ± 20 0.681
Absent 20 ± 14
Vascular Invasion 
Present 5 ± 2 .0061
Absent 60 ± 10
Atypia 
low 26 ± 13 0.319
Moderate 65 ± 9
Hemoglobin 
≤ 12  26 ± 19  0.527
>12 42 ± 28
Liver enzymes 
abnormal 26 ± 11 0.04
normal 65 ± 21
Alkaline phosphatase 
abnormal 65 ± 44 0.682
normal 42 ± 17
Albumin 
abnormal 5 ± 30 0.9
normal 42 ± 19
Alfa fetoprotein 
abnormal 20 ± 21 0.672
normal 42 ± 21
TNM 
Stage I and II 65 ± 14 0.693
III 60 ± 12
IV 8 ± 8
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